[{"id":"24c3c78a-e1db-479c-9eeb-d51b3073b8a7","acronym":"r/r B-NHL","url":"https://clinicaltrials.gov/study/NCT06364852","created_at":"2024-04-15T18:25:43.339Z","updated_at":"2024-07-02T16:35:09.799Z","phase":"Phase 1","brief_title":"An Evaluation of LY007 Cell Injection for r/r B-NHL","source_id_and_acronym":"NCT06364852 - r/r B-NHL","lead_sponsor":"Ruijin Hospital","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LY007"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 12/25/2021","start_date":" 12/25/2021","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2024-04-15"},{"id":"099bccbb-36d2-4595-985a-23305468fb81","acronym":"r/r B-NHL","url":"https://clinicaltrials.gov/study/NCT06279611","created_at":"2024-02-29T02:32:51.155Z","updated_at":"2024-07-02T16:35:17.125Z","phase":"Phase 1","brief_title":"An Evaluation of LY007 Cell Injection for r/r B-NHL","source_id_and_acronym":"NCT06279611 - r/r B-NHL","lead_sponsor":"Shanghai Longyao Biotechnology Inc., Ltd.","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LY007"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 12/25/2021","start_date":" 12/25/2021","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2024-02-28"},{"id":"9b122a82-5422-4557-a5ae-bbd9d59b5630","acronym":"","url":"https://clinicaltrials.gov/study/NCT04169932","created_at":"2021-01-18T20:20:37.763Z","updated_at":"2024-07-02T16:36:53.359Z","phase":"Phase 1","brief_title":"The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT04169932","lead_sponsor":"Shanghai Longyao Biotechnology Inc., Ltd.","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LY007"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/22/2019","start_date":" 11/22/2019","primary_txt":" Primary completion: 11/22/2022","primary_completion_date":" 11/22/2022","study_txt":" Completion: 11/22/2022","study_completion_date":" 11/22/2022","last_update_posted":"2019-11-20"}]